UNSPSC 51351524: Medroxyprogesterone caproate

This classification denotes a therapeutic progestin with the molecular formula C28H42O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GNC5BCM98A, chemically known as pregn-4-ene-3,20-dione, 6-methyl-17-((1-oxohexyl)oxy)-, (6.alpha.)-, but more generally known as medroxyprogesterone caproate, which bears US NIH Compound Identifier 62997. European Medicines Agency schedules medroxyprogesterone caproate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08699MIG.

Most nations, for tariff purposes, schedule medroxyprogesterone caproate under HS 29372300. SMILES: CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C)C)C(=O)C.

UNSPSC 51351524 Medroxyprogesterone caproate is a Commodity code representing specific pharmaceutical active ingredients and formulations that state and local health systems and correctional facilities procure through cooperative purchasing agreements and multi-vendor contracts. Recent activity shows state and local governments sourcing this and related generic pharmaceutical products as part of broader formulary acquisitions tied to authorized pharmaceutical wholesalers, with purchasing managed through cooperative purchasing vehicles and governed by FDA compliance, Good Manufacturing Practices certification, and Drug Supply Chain Security Act requirements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with a March 26, 2026 proposal deadline. The procurement spans participating state and local government facilities in Minnesota, Oregon, and other participating jurisdictions, requiring vendors to supply through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must demonstrate cGMP and DSCSA compliance, maintain contractual relationships with at least two of the three wholesalers with chargeback systems in place, carry commercial general liability insurance of $5,000,000 per occurrence and professional liability of $2,000,000, and submit detailed product information including NDC codes, SKUs, UPCs, strength, dosage form, and packaging configuration. Evaluation weights pricing competitiveness at 75 percent, with fixed pricing for contract term at 10 percent and compliance with administrative requirements (EDI capability, data format, 3 percent administrative fee agreement) comprising the remainder. The contract term is two years for new responders with optional extensions through June 30, 2028 for incumbent amendments, and MMCAP reserves multi-award authority based on therapeutic considerations and member-specific needs.